Bernstein Maintains Outperform on Guardant Health, Raises Price Target to $200
Bernstein analyst Eve Burstein maintains Guardant Health (NASDAQ: GH ) with a Outperform and raises the price target from $175 to $200.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.